Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Autoimmune Liver Disease
What is your approach to treatment of immune-mediated overlap syndromes, such as AIH-PBC?
Related Questions
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
What is your approach to the management of anti-pruritic therapies in patients with cholestatic liver disease?
How do you prefer to manage IgG-4 related hepato-biliary disease, especially if there are similarities in imaging findings to other immune mediated liver diseases?
What patient factors guide your selection of maintenance therapies for a patient with auto-immune hepatitis?
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
When would you choose to measure a patient's spleen stiffness?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
What role do you see for albumin infusions in patients with hypoalbuminemia to help assist in volume status, outside of its use in replenishment after a large volume paracentesis or renal dysfunction?
What factors into your choice to use craving-related medications (e.g., baclofen, naltrexone, acamprosate, etc.) in the management of alcohol use disorder?
How do you determine when you would treat an identified spleno-renal shunt and how?
